| Code | CSB-RA004929MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Isatuximab-IRFC, targeting CD38, a type II transmembrane glycoprotein extensively expressed on multiple myeloma cells and various immune cells. CD38 functions as both an ectoenzyme with NADase and ADP-ribosyl cyclase activities and a receptor involved in cell adhesion and signal transduction. This multifunctional protein plays critical roles in calcium signaling, immune regulation, and metabolic processes. Aberrant CD38 expression is characteristic of hematological malignancies, particularly multiple myeloma, making it a valuable therapeutic target and biomarker in oncology research.
Isatuximab-IRFC is a clinically approved anti-CD38 antibody that induces tumor cell death through multiple mechanisms including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct apoptosis induction without crosslinking. This biosimilar antibody serves as an essential research tool for investigating CD38-mediated pathways, evaluating immune responses in cancer models, and studying mechanisms of action in multiple myeloma and other B-cell malignancies. It enables researchers to explore CD38 biology and antibody-based therapeutic strategies in preclinical studies.
There are currently no reviews for this product.